For every 10 innovative medicines needed by Greek patients, the Government funds fewer than 2! PhARMA Innovation Forum (PIF) expresses its deep concern over the critical situation facing the hospital medicines reimbursement system in Greece. Data from the first half of 2025 reveal an unprecedented reality: clawback on hospital medicines reached 80,7%, marking a further…
Focusing on the sustainability of the pharmaceutical system, the strengthening of innovation, and the shaping of a modern pharmaceutical policy framework, PhARMA Innovation Forum (PIF) participated in the 7th Health Conference of ProtoThema. PIF President and Roche Hellas General Manager, Ms. Kavita Patel, took part in the panel discussion titled “Pharmaceutical Policy: Innovation, Production and…
With a focus on accelerating Greek patients’ access to innovative therapies and addressing major challenges in pharmaceutical policy, PhARMA Innovation Forum completed its electoral process for the appointment of its new Board of Directors on Friday, May 15. The high level of participation and the spirit of unity among its 31 member companies confirmed PIF’s…
The need for a structural reform that will transform Greece into a regional leader in digital health is highlighted by the joint White Paper of the Hellenic Cancer Federation – ELLOK, the PhARMA Innovation Forum (PIF), and i-HD (European Institute for Innovation through Health Data). The policy paper, entitled “European Health Data Space (EHDS) in…
Labrina Barmpetaki, PIF President: “We’re not just asking for access to innovation — we’re asking for it to be properly valued and rewarded!” Pharma Innovation Forum at the Delphi Economic Forum 2026: Innovation in healthcare requires access, sustainability, and shared responsibility. Pharmaceutical innovation and especially the ability of the healthcare system to translate it into real access and value for…
The highest clawback in the EU, the suspension of innovative cancer therapies, the increasing delays in the arrival of new treatments, and disinvestment in innovation create a worrying environment that requires shared responsibility and immediate action. PhARMA Innovation Forum (PIF), representing 30 leading biopharmaceutical companies engaged in the research, development, and provision of innovative therapies,…
Innovation is not simply the introduction of new medicines. It is a catalyst that improves quality of life, reduces hospitalization and disability, and enhances productivity and societal participation. For Greece’s health system- already under pressure from demographic ageing, chronic disease burdens, and constrained budgets- innovative therapies and digital tools offer a path toward sustainability. They…
Daniel Paksy, Managing Director, Johnson & Johnson Innovative Medicine Greece & Romania In recent years, the word ‘innovation’ has become firmly embedded in almost every aspect of our daily lives. We hear it from scientists and business leaders across sectors, and it is often the standard answer when discussing progress and development. In pharmaceutical…
Anthony Aouad, Sanofi General Manager Greece, Hungary & Ukraine To understand what biopharmaceutical innovation truly means, let’s consider the moment when a patient, having heard the difficult news of diagnosis, asks the doctor: “Is there a treatment?” More and more today, the answer is “yes” – yes, there is a treatment that can change…
The advancement of biopharmaceutical innovation in Greece is crucial in shaping the future of health, significantly impacting patients’ lives, the economy, and the society. New technologies are transforming the way care is delivered, with the patient always at the center. The integration of tools such as telemedicine, electronic health records, health apps, and artificial intelligence…
